Do you know what Advanced therapy medicinal products (ATMPs), Digital health and Artificial Intelligence (AI), Real-World Evidence (RWE) and Health Technology Assessment (HTA) and the COVID-19 pandemic have in common? These are the four main topics in the scope of the upcoming Biotech Atelier 2020.
On 25th September 2019 Biotech Atelier 2.0 welcomed 240+ attendees with expertise and interest in biotechnology, IT, healthcare, life science, pharma, regulatory and law. Amongst them were 48 high-profile speakers (scientists, entrepreneurs, futurists, business leaders and investors), who led 10+ hours of engaging panel discussions across 18 topics. They included AI and IT in Medicine, ATMPs, the MEGA project, Biobanking and Biomarkers, Clinical Trials, Genomics, Personalized Medicine, Access to Funding, and much more. One fourth of all guests were high-profile decision makers – board members, c-level executives, heads and directors.